The importance of the second generation adjuvanted systems in "new" vaccines;Význam druhé generace adjuvantnich prostředků v "novych" vakcínách

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 14, Issue 1, 2008, Pages 5-12

  Beran, Jiří ^a,b,c  

^a Lékařská Fakulta ^*  (Czech Republic)

^b IPVZ   (Czech Republic)

^c Poliklinika II   (Czech Republic)

Author keywords

Adjuvanted system; AS04; Cervical cancer; Immunization; MPL; Papillomavirus; Vaccination

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; AS 04; HEPATITIS B VACCINE; HERPES VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; DRUG RESEARCH; DRUG TARGETING; GENITAL HERPES; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MALARIA; MONOTHERAPY; REVIEW; VIRUS ATTENUATION; VIRUS INACTIVATION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; HEPATITIS B VACCINES; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; PAPILLOMAVIRUS VACCINES; VACCINES;

EID: 41549147765     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Beran J, Havlík J, Vonka V. Očkování: minulost, přítomnost, budoucnost. Galén, Praha, 2005, 348 s.
2. Zur Hausen H. Human genital cancer. synergism between two virus infections or synergism between a virus infection and initiating events? Lancet 1982;2(8312): 1370-1372.
3. Lindblad Eb. Aluminium adjuvants - in retrospect and prospect. Vaccine. 2004 Sep 9;22(27-28):3658-68.
4. Glenny At, Pope Cg, Waddington H, Wallace U. Immunological notes XVII to XXIV. J Pathol 1926;29:31-40.
5. Glenny At., Buttle Gah., Stevens Mf. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. J Pathol 1931;34:267-75.
6. Ericsson H. Purification and adsorption of diphtheria toxoid. Nature 1946;158: 350-1.
7. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T. Different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003;171(10):4984-9.
8. Hořejší V, Barto̊ňková J. Základy imunologie. 3. vydání. Praha: Triton, 2005, 280 s.
9. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2(8):675-680.
10. Schnare M, Barton G M, Holt A C, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2(10):947-950.
11. Schwarz TF. Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Review of Obstetrics & Gynecology, May 2007, Vol. 2, No. 3, Pages 293-303.
12. Baldridge Jr., Yorgensen Y, Ward Jr., Ulrich Jt. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000;18(22):2416-2425.
13. De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000;12(6):807-815.
14. Giannini SI, Hanon E, Moris P. et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccinee formulated with the MPL/ aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006 Aug 14;24(33-34):5937-49.
15. Boland G, Beran J, Lievens M. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine. 2004 Dec 2;23(3): 316-20.
16. SPC vakcíny Fendrix publikované dne 22/12/2005 na http://www.emea.eu.int//index/indexh1.htm. Přístup dne 28/09/2007.
17. Tong NK., Beran J., Kee SA. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005 Nov;68(5):2298-303.
18. Harper D. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trials. Lancet 2004;364:1757-65.
19. Osterhaus Ad. Pre- or post-pandemic influenza vaccine? Vaccine. 2007 28;25(27): 4983-4.
20. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. The Lancet 2004;364:1757-1765.
21. Alonso PL, Sacartal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. The Lancet 2004;364:1411-1420.
22. Stanberry LR, Sprunance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21):1652-1661.